🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Technology Sector SEC Filings — March 02, 2026

Across the 8 S&P 500 Technology stream filings dated around March 2, 2026, dominant themes include aggressive capital returns via share repurchases in software firms (Klaviyo $500M program + $100M ASR imminent; Synopsys $250M ASR), signaling strong management conviction amid neutral governance changes (Datadog board expansion, Broadcom director retirement). Intuitive Surgical's completion of a key acquisition enhances its distribution footprint, while Murphy USA (outlier retail) reports mixed 2025 results with EBITDA up slightly YoY to $1.02B from $1.01B but fuel volumes down 3.0% YoY and OpEx up 5.8% to $763M, issuing cautious 2026 guidance for continued fuel declines (-3.0% to -1.0%). ACNB's note redemption and C2 Blockchain's micro-equity raise highlight debt management and dilution risks in non-core names. Portfolio-level trends show 2/8 companies pursuing major buybacks (positive for EPS accretion), limited YoY growth visibility except Murphy's flat contributions, and forward catalysts like ASR settlements and redemptions creating near-term volatility. Overall sentiment leans positive from capital allocation (3 positive filings) but mixed ops signal sector resilience with pockets of pressure; investors should prioritize buyback initiators for alpha amid low M&A disclosure.

2 high priority 6 medium 8 total filings
· daily

Nasdaq 100 Stocks SEC Filings — March 02, 2026

Across these 6 NASDAQ-100 filings dated March 2, 2026, overarching themes include strategic expansions in AI/security (AITX), resilient retail operations amid headwinds (Murphy USA), board governance refreshes (CCC, Broadcom), biotech capital access (Intellia), and M&A completion in robotics (Intuitive Surgical), with 5/6 filings carrying positive sentiment versus one mixed. Key period-over-period trends highlight Murphy USA's Adjusted EBITDA up slightly YoY to $1.02B from $1.01B despite -3.0% same-store fuel volume decline and +5.8% store OpEx to $763M, marking an outlier in detailed financial disclosures while others focus on non-financial catalysts. Critical developments like Intellia's 38% ATM capacity expansion to $1.035B and Intuitive's acquisition closure signal funding flexibility and market penetration, but Murphy's FY2026 guidance flags ongoing -3.0% to -1.0% fuel volume declines. Portfolio-level patterns show tech/AI firms pursuing partnerships and audits for credibility (AITX SOC 2), contrasting retail's flat fuel contribution amid competition from 600+ new stores since 2020. Overall, bullish operational momentum in 4/6 companies supports near-term upside, tempered by retail sector pressures.

3 high priority 3 medium 6 total filings
· daily

Dow Jones 30 Stocks SEC Filings — March 02, 2026

Across 92 SEC filings from Dow Jones 30-related and blue-chip streams dated March 2, 2026, dominant themes include robust revenue growth in energy/LNG (e.g., Venture Global +177% YoY to $13.8B) and biotech (e.g., Xeris +43.7% FY revenue), offset by mixed results in cruises and E&P with margin pressures; banking sector shows aggressive M&A consolidation (7+ deals adding billions in assets). Period-over-period trends reveal 18/92 companies with >30% YoY revenue growth (avg +65%), but 12/92 reported net losses or impairments amid higher expenses; capital allocation leans bullish with 9 dividend hikes (e.g., Amex +16%) and 5 buyback expansions (e.g., Klaviyo $500M). Insider activity is sparse but mixed (Coke PDMR sales $1.4M countered by buys), while forward guidance is raised in 15 cases (e.g., Dave 25-28% revenue growth). M&A activity surges (12 deals, e.g., Warner Bros $31/share cash merger), signaling portfolio optimization, but regulatory risks loom (Elevance CMS sanctions). Overall, bullish momentum in healthcare/tech/energy supports DJ30 outperformance, with banking M&A as a key alpha driver amid 5.3x avg net leverage stability.

45 high priority 47 medium 92 total filings
· daily

US SEC Filings Daily Market Digest — March 02, 2026

Across 327 SEC filings for March 2, 2026, mixed sentiment dominates (appearing in 15+ filings like Norwegian Cruise, Venture Global, Ruger), with revenue growth strong in energy (Venture Global +177% YoY to $13.8B, Kosmos Q4 +4% QoQ) and biotech but profitability pressures evident (Ruger FY net loss vs prior profit, WhiteHorse NII -29.8% YoY). Biotech shines with positive Phase 3 data (DBV 46.6% responders, United Therapeutics 55% risk reduction) and catalysts into H1 2026 (BLA submissions, PDUFA Mar 20). M&A activity surges (Warner Bros $81B deal, Malibu Boats accretive acquisition at 7.2x EBITDA, HBT $1.8B assets), alongside capital returns (ADMA $200M buybacks, Klaviyo $500M program). Period trends show YoY revenue acceleration in 20+ cos (avg +20-50% in LNG/pharma) but margin compression in 10+ (avg -100-200bps consumer/manufacturing). Insider sales at Coca-Cola Europacific (execs sold $1.4M) contrast buybacks signaling conviction elsewhere. Forward guidance mixed: flat yields (Norwegian), $5.2-5.8B EBITDA (Venture), but Whirlpool EPS cut ~$1. Implications favor selective longs in biotech/energy catalysts, caution consumer/retail amid traffic declines.

132 high priority 195 medium 327 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 02, 2026

Across 51 filings in the S&P 500 Consumer Discretionary intelligence stream (with heavy financial services overlap), Q4/FY2025 results show mixed performance: 6/10 reporting companies experienced YoY revenue declines averaging -12% (e.g., Core Scientific -16%, Crawford -11%, Mobile Infra -4.3%), driven by weather disruptions, lower claims/volumes, and transients, while outliers like Life360 (+32% revenue) and Riot Platforms (+72%) posted strong growth. Bank/financial M&A dominated with 8 completions (e.g., HBT Financial, Farmers National, First Mid) boosting assets 30-42% on average, signaling consolidation. Capital allocation remains shareholder-friendly: 5 buyback/dividend hikes (Proficient $15M repurchase, WhiteHorse insiders bought $8M shares), but insider sales in CCE (execs sold $1.4M) flag caution. Forward guidance stable (Mobile Infra +4-7% 2026 rev/NOI growth), with power expansions (Core Scientific +730MW) and venue reopenings as catalysts. Portfolio trend: margin volatility (gross margins expanded in Life360 +3pp, compressed elsewhere), liquidity strong ($1.9B Riot, $533M Core), but restatements (Core Scientific) and debt rises (TPG 2.14x to 3.0x) add risks. Implications: Favor M&A beneficiaries and growth outliers for upside, monitor weather-sensitive ops.

22 high priority 29 medium 51 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — March 02, 2026

Across 35 filings in the USA S&P 500 Healthcare stream (with broader market exposure including biotechs, insurers, banks, and others), overarching themes include robust biotech pipeline advancements and financings (e.g., NewAmsterdam's Phase 3 successes, Zymeworks' $250M royalty deal), active M&A/integration (9 deals like HBT Financial, Rallybio, Intuitive Surgical), steady capital returns via buybacks/dividends (Tidewater $500M auth, Stewart $0.525/share), but mixed financials with 6/12 reporting entities showing YoY revenue declines (avg -15%, e.g., Core Scientific -16%, Zymeworks Q4 -92%). Healthcare-specific trends highlight positive clinical catalysts (NewAmsterdam 35-40% LDL-C reduction, Tyra data readouts 2026) offset by insurer risks (Elevance CMS sanctions threat), while period comparisons reveal biotech net losses widening (Tyra FY +39% to $119.9M) amid R&D ramps (+27-29% YoY). Insider activity mixed with sales at Coca-Cola Europacific ($1.41M total) but routine buys; capital allocation favors deleveraging (Peapack $100M redemption) and repurchases. Portfolio implications: overweight biotechs with 2026 catalysts, monitor insurer regulatory overhangs for near-term volatility.

14 high priority 21 medium 35 total filings
· daily

Global High-Priority Regulatory Events — March 02, 2026

Across 158 filings on March 2, 2026, dominant themes include a surge in US banking M&A (e.g., HBT Financial +42% assets, Farmers National +42% assets to $7.4B), positive capital allocation via buybacks (Go Fashion ₹65Cr) and accretive acquisitions (ITT SPX FLOW $4.8B, Malibu Boats $175M at 7.2x EBITDA), contrasted by distress in Indian firms with defaults (Siti Networks ₹1,206Cr claims, Ansal Housing ₹50Cr principal) and tax raids (Greenpanel). Period trends show revenue strength in select names (Dave Inc. Q4 +62% YoY to $164M, MongoDB Q4 +27% YoY to $695M, Kosmos Q4 prod +4% QoQ) but mixed margins (MongoDB flat GAAP gross at 73%). Leadership transitions are prevalent (neutral sentiment, e.g., Eaton CFO change, Civista CEO succession), with forward catalysts like open offers (Shantai Apr 2026) and deal closes (EQV Mar 4). Portfolio-level: Banking consolidation boosts scale (avg +35-42% assets in deals), Indian realty/media under pressure (5/10 high materiality negatives), energy/biotech M&A outliers for growth. Implications: Favor US consolidators for synergies, avoid Indian defaulters amid CIRP; watch SPAC de-SPACs and debt refinancings for liquidity plays.

158 high priority 158 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 02, 2026

Crane Harbor Acquisition Corp. (CHAC), the sole filing in this Executive Compensation Insights stream, details a high-materiality (9/10) SPAC business combination with Xanadu Quantum Technologies Inc. via NewCo, with neutral sentiment and no disclosed prior period financial performance, metrics, or executive compensation specifics. The DEFM14A proxy seeks shareholder approval at an extraordinary general meeting on March 19, 2026, for the merger under a November 3, 2025 agreement, including a continuance from Cayman Islands to Ontario and massive share issuances (515M Class A Multiple Voting Shares, 79M Class B Subordinate Voting Shares). PIPE financing at $10.00 per share from Crane Harbor Sponsor affiliates underscores sponsor commitment amid no YoY/QoQ trends available. This positions CHAC for entry into quantum technologies, a high-growth sector, but highlights typical SPAC risks like dilution and approval dependency. No insider trading, capital allocation details (e.g., dividends/buybacks), or forward-looking financial guidance beyond transaction timelines are enriched, limiting period comparisons but flagging the March 19 catalyst as pivotal for market implications. Overall, the filing signals concentrated event-driven opportunity in quantum computing via SPAC de-SPACing.

1 high priority 1 total filings
· daily

US Executive Officer Management Changes SEC — March 02, 2026

Across 53 SEC filings on US executive and director changes from March 2, 2026 (covering events Feb-Mar 2026), the dominant theme is a surge in leadership transitions with 28 appointments/promotions (e.g., experienced CFOs/CEOs in Eaton, Asana, L3Harris) signaling continuity and growth conviction, contrasted by 19 resignations/retirements (e.g., planned in Civista, chaotic in BiomX/TON Strategy) and 6 restructurings/comp changes. Period-over-period trends show robust revenue growth in reporting firms: MongoDB Q4 FY2026 +27% YoY to $695.1M, Atlas +29% YoY; Dave Inc Q4 2025 +62% YoY to $163.7M, FY +60% YoY; Great Elm Q4 NII +50% QoQ to $0.31/share, though NAV -20% QoQ. Positive sentiment in 14/53 filings (tech/finance hires), negative/mixed in 9 (biotech distress), neutral dominant. Portfolio-level patterns: Banking sector orderly CEO successions (Civista, First Bancorp), tech internal promotions amid strong growth (Asana CFO, MongoDB CCO), biotech high turnover risks. Market implications: Bullish for stable transitions with growth backdrops (e.g., Eaton $27.4B 2025 rev), bearish for governance disputes (TON Strategy CEO firing with self-dealing claims); alpha in pre-IPO catalysts (L3Harris Missile Solutions) and buyback hikes (Dave $300M authorization).

53 high priority 53 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — March 02, 2026

Across 49 filings in the USA Corporate Distress & Bankruptcy stream, a bifurcated landscape emerges: 7 companies (14%) face acute delisting risks or compliance issues (e.g., Allurion, Graphjet, Iterum), while 70% involve proactive capital raises, debt refinancings, or M&A to extend runways amid distress signals, with no broad YoY revenue declines but frequent mentions of prior weak equity/market cap metrics. Biotech/pharma dominates (20+ filings) with mixed M&A outcomes like Pulmatrix termination but Gyre-Cullgen pivot, alongside heavy equity/debt issuances (e.g., $250M Zymeworks royalty note, $1.5B Targa notes) signaling liquidity preservation over growth. Forward-looking catalysts cluster in Q2 2026 (merger closes, approvals), with capital allocation tilting to debt exchanges/raises vs buybacks/dividends, reflecting strained balance sheets. Portfolio-level trends show 12/49 positive financings extending runway >2028 (e.g., Zymeworks beyond 2028), but 5 mixed restructurings introduce dilution risks. Implications: Short small-cap distress names pre-delisting, long M&A targets at premiums (AES 40.3%), monitor Q2 catalysts for turnarounds.

49 high priority 49 total filings
· daily

US SEC Trading Suspension Halt Orders — March 02, 2026

Across six US-listed small-cap companies in the Trading Suspensions stream (period March 2, 2026), regulatory pressures dominate with Nasdaq and NYSE delisting risks centered on bid price deficiencies, low stockholders' equity/market cap, and MVLS shortfalls; HCW Biologics (HCWB) is the sole positive outlier, regaining full Nasdaq Capital Market compliance on February 26, 2026, enabling capital access for immunotherapies. Graphjet Technology and Iterum Therapeutics face affirmed delistings with trading suspensions (Nov 13, 2025, and March 5, 2026, respectively), signaling severe distress and potential wind-downs. Mixed outcomes for Allurion Technologies (NYSE appeal post-FDA approval Feb 20, 2026, debt-to-equity swap), Northann Corp (compliance plan accepted to June 8, 2027), and My Size (180-day bid price cure to Aug 31, 2026). No uniform period-over-period financial trends evident due to regulatory focus, but forward-looking compliance extensions provide temporary trading continuity for 4/6 firms. Biotech/healthcare firms (3/6) show heightened vulnerability, with capital raises/debt restructurings as common countermeasures. Portfolio implication: Avoid delisted names; monitor appeals for short-term trading pops.

6 high priority 6 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 02, 2026

Across 49 SEC filings on USA Board Room Changes from March 2, 2026, the dominant theme is proactive board and C-suite refreshments, with 25+ new appointments/promotions of experienced executives (e.g., finance vets to banking/tech boards) outpacing 15+ resignations/retirements, often planned and amicable, signaling strong governance and strategic pivots amid growth pressures. Period-over-period trends show outliers like Dave Inc. Q4 2025 revenue +62% YoY and MongoDB +27% YoY with FCF +672% to $176.7M, contrasting Great Elm's NII +50% QoQ but NAV -20% QoQ to $8.07/share; aggregate, 3/5 financial reporters exhibited revenue acceleration averaging +47% YoY. Forward-looking catalysts include Dave's FY2026 revenue guide +25-28% to $690-710M, MongoDB FY2027 non-GAAP op income $545-565M, and enCore's Verdera share distribution post-resale registration. Capital allocation leans shareholder-friendly with Dave raising buybacks to $300M (+140%), Great Elm $0.30/share Q1 dividend (19.2% yield), but risks emerge in biotech distress (BioAtla 70% workforce cut). Banking sector orderly CEO successions (Civista, First Bancorp) highlight continuity; tech/biotech churn mixed but net positive. Portfolio implication: Favor leadership upgrades in growth sectors, monitor biotech turnarounds.

49 high priority 49 total filings
· daily

US Merger & Acquisition SEC Filings — March 02, 2026

A surge in US M&A and takeover activity dominates the 29 filings from March 2, 2026, with 12 completed mergers/acquisitions (primarily banking consolidations adding $20B+ in combined assets) and robust SPAC developments including 4 IPOs raising $800M+, 3 extensions, and 2 business combination approvals/proxies. Banking sector leads with 7 deals (e.g., HBT Financial +$1.8B assets, Farmers National +42% to $7.4B), driving footprint expansions in Midwest/East Coast without reported declines. Positive sentiment prevails in 17/29 filings (avg materiality 8.7/10), bolstered by accretive deals (e.g., Malibu Boats 7.2x EBITDA, Crexendo to $100M run-rate), though mixed signals in energy (Kosmos Q4 loss $377M despite +4% QoQ production). SPACs show high activity but delays/extensions flag execution risks. Forward-looking catalysts cluster in Q1 2026 (closings, earnings), with no insider trading disclosed but board additions signaling integration confidence. Portfolio trend: Asset growth avg +30% in banks vs sector contraction risks elsewhere; implications favor M&A arbitrage and regional bank longs amid consolidation wave.

29 high priority 29 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 02, 2026

Across 121 overnight SEC filings, dominant themes include a surge in M&A activity (10+ deals like Warner Bros. Discovery's $81B merger with Paramount Skydance, HBT Financial's completion with CNB adding $1.8B assets, Malibu Boats' $175M Saxdor acquisition), robust biopharma catalysts (United Therapeutics' 55% risk reduction in Phase 3, Rhythm's PDUFA March 20 for setmelanotide, DBV's Phase 3 responder rate 46.6%), and mixed financial results with 15+ companies showing YoY revenue growth averaging 30-50% (e.g., Venture Global +177%, RadNet +14.8%) but margin pressures in consumer/energy (avg -100bps compression in 8/20 cases). Capital allocation leans bullish with 12+ share repurchase programs (Klaviyo $500M, ADMA $200M, Zymeworks $62.5M used), dividend hikes (PROG +7.7%), and debt reductions (Bandwidth repurchased $100M notes). Energy/oil firms highlight strong production/revenue but impairments (Kosmos Q4 loss $377M), while REITs show leasing gains (Macerich 7.1M sq ft). Portfolio-level: 60% positive/mixed sentiment, implying pre-market upside in biopharma/media, caution in cruise/retail; no major insider selling patterns, but buys/exercises signal conviction (WhiteHorse 1.1M shares $8M, Ramaco CEO options). Forward catalysts cluster in H1-H2 2026 (NDAs, earnings, closings).

41 high priority 80 medium 121 total filings
· daily

New Federal Contractors — March 01, 2026

A single massive $20.65B cost-plus award fee contract for Lockheed Martin Services to manage DOE's Y-12 plant through 2027 dominates this period, signaling exceptional long-term revenue stability in government-owned facilities operations. Zero outlays despite the 43-year history highlight execution risks amid DOE budget dependence. Investors should prioritize Lockheed Martin for defense-industrial exposure while monitoring funding triggers.

1 total filings
· daily

Contract Deobligations Alert — March 01, 2026

A single massive $20.65B long-term DOE contract for Lockheed Martin Services underscores exceptional revenue visibility through 2027 in Y-12 nuclear facilities management, signaling bullish stability for Lockheed Martin Corp amid full and open competition. Zero outlays to date highlight execution risks but minimal obligation gaps suggest fully funded potential. Investors should prioritize monitoring DOE budgets for reimbursements and follow-on opportunities in GOCO operations.

1 total filings
· daily

Contract Option Exercises — March 01, 2026

Lockheed Martin Services secures a $20.65B cost-plus award fee contract with DOE for Y-12 plant management through Feb 2027, signaling strong revenue visibility in government-owned contractor-operated (GOCO) facilities. Despite zero outlays to date, the fully funded structure and full competition award highlight stability in facilities support services. Investors should monitor DOE budgets for execution risks amid this outsized single-contract concentration.

1 total filings
· daily

All DOE Contracts — March 01, 2026

A single $20.65B DOE contract for Lockheed Martin underscores exceptional long-term revenue stability in Y-12 plant management through 2027, providing high-confidence bullish signal for the company amid full and open competition. No outlays despite 43-year history flags execution risks tied to DOE budgets, warranting caution on near-term cash flows. Fully funded structure and follow-on potential position Lockheed as a prime watch item in facilities support services.

1 total filings